MYELODYSPLASTIC SYNDROMES

This study tests whether combining three drugs—tacrolimus, methotrexate, and a new dosing schedule of anti-thymocyte globulin—can prevent acute graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia. About 29 adults aged 18-60 w…

This early-phase study tests a new stem cell transplant method for people with aggressive or returning acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially processed donor cells to reduce the risk of graft-versus-host disease, with the goal…

This study tests a new experimental drug called EP0042, alone or with other cancer treatments, in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The main goal is to find a safe dose that might work against the cancer. About 70 people will take part in…

This study tests a low-dose weekly combination of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can control the disease while causing fewer treatment delays or interrupti…

This study tests whether giving two drugs (decitabine and filgrastim) after a stem cell transplant can safely prevent leukemia or related blood cancers from coming back in children and young adults. About 37 participants with acute myeloid leukemia, myelodysplastic syndromes, or …

This early-phase study tests a new way to prepare donor stem cells (called Orca-Q) for transplant in people with certain blood cancers like leukemia. The goal is to see if this engineered graft is safe and helps the body accept the new cells without serious side effects. About 30…

This study tests a special stem cell transplant that removes certain immune cells to lower the risk of graft-versus-host disease (GVHD) and reduce the need for long-term immune-suppressing drugs. It is for people with inherited bone marrow failure disorders like Fanconi anemia. T…

This early-phase trial tests whether specially trained natural killer (NK) cells can safely prevent blood cancers like leukemia from coming back after a stem cell transplant. About 15 adults with high-risk disease will receive an infusion of these cells plus a supportive drug. Th…

This early-stage trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in people with advanced blood cancers who receive a stem cell transplant from a partially matched donor. The main goal is to see if this approach red…

This study tests whether a special exercise program combined with a vitamin-like supplement (called NR) can help teens and young adults who had a bone marrow transplant rebuild lost muscle and improve their fitness. About 80 participants, ages 10 to 30, will be randomly assigned …

This study tests whether using two different stem cell donors together can help people with certain blood cancers (like leukemia and myelodysplastic syndromes) live longer without their cancer coming back. About 36 participants will receive a transplant from a half-matched family…

This study tests a combination of interferon-γ and donor immune cells for people whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The goal is to see if this treatment can control the disease and improve survival. About 45 adult…

This study tests a pill called olutasidenib in people with certain early blood disorders (CCUS, lower-risk MDS, or CMML) that have a specific gene change (IDH1 mutation). The goal is to see if the drug can control the disease and improve blood counts. Fifteen participants will re…

This early-phase study tests adding the drug venetoclax to standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). The goal is to find the safest dose and see if the combination works better than chemo alone. …

This study is testing a new drug called BGB-11417 for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The drug works by blocking a protein that helps cancer cells survive. The study will find safe doses and see if the drug …

This study tests a drug called pacritinib for people aged 12 and older with myelodysplastic syndromes (MDS) or related blood disorders. The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to 8 years, wit…

This study is for people with certain blood cancers (like leukemia) who are getting a half-matched bone marrow transplant. Researchers are adding a dose of specially grown immune cells (gamma delta T-cells) after the transplant to see if it can kill any leftover cancer cells whil…

This early-phase study tests a new drug called danvatirsen, first alone and then combined with venetoclax, in 38 adults whose acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have returned or not responded to standard treatments. The goal is to see if the drug is s…

This study tests a stem cell transplant approach for people with blood cancers like AML and MDS. It uses milder chemotherapy (treosulfan and fludarabine) followed by a donor stem cell infusion, plus drugs to prevent graft-versus-host disease. The goal is to improve survival at 10…

This study tests a combination of the drug venetoclax with a standard chemotherapy-like agent, plus an infusion of immune cells from a partially matched donor, for people with intermediate- to high-risk myelodysplastic syndromes (MDS) who cannot have a standard stem cell transpla…

This study tests whether adding high-dose vitamin C to a standard chemotherapy drug (azacitidine) can help adults with a bone marrow disorder called myelodysplastic syndrome (MDS). About 38 participants with higher-risk MDS will receive the combination intravenously. The goal is …

This early-phase study tests a new drug called SX-682, alone or with decitabine, in people with myelodysplastic syndrome (MDS), a type of bone marrow cancer. The main goal is to find the safest dose and identify side effects. About 151 adults who have not responded to prior treat…

This study tests whether adding specially prepared donor immune cells can help children recover from stem cell transplants faster and avoid dangerous infections. Participants are children under 25 with high-risk blood cancers who have already received a transplant. The goal is to…

This study is for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have received a stem cell transplant from a half-matched donor. After the transplant, participants will receive extra immune cells called natural killer (NK) cells from the same dono…

This study is for people with a low-risk form of myelodysplastic syndrome (MDS) who do not have ring sideroblasts and whose anemia has not improved with standard treatment. The trial tests whether adding a drug called luspatercept to another drug (ESA) works better than luspaterc…

This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning in adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia after a stem cell transplant. About 7…

This study tests a new automated method to select specific stem cells (CD34+) for patients with blood cancers who need a stem cell boost or second transplant. The goal is to lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the pa…

This study looks at how well umbilical cord blood stem cells from unrelated donors can restore blood cell counts in people with serious blood cancers, immune deficiencies, or genetic disorders. Researchers will track how often the transplant succeeds, how long it takes for blood …

This study tests adding the drug momelotinib to standard treatment for people with certain rare blood cancers (MDS/MPN and chronic neutrophilic leukemia). The goal is to better control the disease, improve symptoms, and help more patients become eligible for a transplant. About 1…

This early-phase study tests an experimental oral drug, GLB-001, in about 48 adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that returned or didn't respond to prior therapy. The main goals are to find a safe dose and check for side effects. Researchers …

This study tests an experimental drug called CTX-712 in adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to or returned after prior treatments. The goal is to find the safest dose and see if the drug can shrink or control the can…

This study tests an investigational drug called elritercept in adults with a bone marrow disorder (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go at least 8 weeks without a transfusion. About 225 participants will recei…

This study tests whether adding venetoclax to the standard chemotherapy before a stem cell transplant can help prevent cancer from returning in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 60 will be rand…

This study tests a rotating combination of four drugs (cladribine, cytarabine, venetoclax, and azacitidine) to see if it can help control higher-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). It is for adults aged 18 and older whose cancer has not …

This early-phase study tests whether adding an experimental drug called defactinib to an approved oral treatment (decitabine/cedazuridine) is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonocytic leukem…

This study looks at how the body handles the cancer drug ASTX727 in people with severe kidney problems compared to those with normal kidneys. About 18 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to see if the drug is safe an…

This study tests an experimental drug called elritercept (KER-050) in about 160 adults with a bone marrow condition called myelodysplastic syndromes (MDS) who have anemia. The main goal is to check the drug's safety and how well people tolerate different doses. Researchers will a…

This study is testing an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can help patients produce enough red blood cells so they no longer need regular blood transfus…

This early-stage study tests a new drug called MGD024 in about 130 adults with certain blood cancers (like leukemia or lymphoma) that did not get better with standard treatments or came back. The main goal is to find a safe dose and understand side effects. Participants receive t…

This study looks at how the cancer drug ASTX727 works in people with moderate or severe liver problems. It includes 27 adults with certain blood cancers or solid tumors. The goal is to understand how the liver affects the drug's safety and processing in the body.

This early-phase study tests a new type of immune cell (CIML NK cells) combined with a low-dose drug (IL-2) in people whose leukemia or related blood cancers have returned after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into rem…

This early-stage trial tests a new daily pill, BH-30236, for adults with acute myeloid leukemia (AML) or a high-risk pre-leukemia condition (MDS) that has returned or not responded to prior treatments. The study will first find the safest dose, then test it alone or with another …

This study tests a personalized cell therapy called Orca-T for 80 adults with acute myeloid leukemia or myelodysplastic syndrome. Participants receive a stem cell transplant with specially processed donor cells designed to reduce complications like graft-versus-host disease. The …

This early-phase study tests a new treatment for adults with acute myeloid leukemia or myelodysplastic syndrome who still have measurable disease after standard therapy. The treatment uses the patient's own blood cells that are specially armed with a bispecific antibody to target…

This study tests a drug called momelotinib in 80 adults with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if the drug can help them go without red blood cell transfusions for at least 12 weeks. The trial has two parts: first to find the best dose, …

This early-stage study tests a new treatment called MNV-201 for people with low-risk myelodysplastic syndrome (MDS), a bone marrow disorder that causes low blood counts. The therapy uses the patient's own blood stem cells enriched with mitochondria from donated placentas to try t…

This study tests a new drug called AND017 for anemia in people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS). The goal is to see if the drug can raise hemoglobin levels or reduce the need for blood transfusions. About 63 participants will r…

This study tests an oral drug (ASTX030) that combines two chemotherapy agents to treat certain blood cancers like myelodysplastic syndromes and acute myeloid leukemia. It aims to see if taking a pill is as effective as getting injections. About 316 adults will participate over ro…

This study looks at whether getting a stem cell transplant right away is as good as getting some treatment first and then the transplant for people with higher-risk myelodysplastic syndrome (MDS). About 236 adults who are eligible for a transplant will be randomly assigned to one…

This early-stage trial tests whether adding decitabine and venetoclax to a standard stem cell transplant is safe for people with high-risk blood cancers like leukemia. About 20 adults aged 18-75 with a matching donor will take part. The goal is to find the best dose that limits s…

This study tests an experimental drug called enzomenib in about 600 people with acute leukemia and certain other blood cancers. The goal is to find the safest dose and see if the drug can shrink or control the cancer. Participants must have cancers that came back or did not respo…

This study tests whether giving a drug combination (decitabine and cedazuridine, or DEC-C) early can prevent myelodysplastic syndromes (MDS) from coming back after a stem cell transplant. About 209 adults who have had a transplant and still have tiny amounts of cancer cells (meas…

This early-stage study aims to find a safe and effective dose of a new oral drug, iadademstat, when given alongside a standard chemotherapy drug, azacitidine. It is for adults with higher-risk forms of myelodysplastic syndrome (MDS), a type of bone marrow cancer. The main goal is…

This study tests whether tranexamic acid, a drug that helps blood clots stay in place, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 adults receiving less-intensive chemotherapy and having low platelet counts w…

This study looks at whether offering blood transfusions at home for people with advanced blood cancers who are in hospice care can improve their quality of life and mood. About 700 adults with relapsed or hard-to-treat blood cancers will take part. The goal is to see if this prog…

This study tests if the drug luspatercept can help people with lower-risk myelodysplastic syndromes (MDS) need fewer blood transfusions. About 40 adults with MDS will receive the drug, and researchers will track side effects and transfusion needs. The goal is to improve quality o…

This study is testing whether giving blood transfusions at home is practical and acceptable for cancer patients who need regular transfusions. About 30 adults with blood cancers or bone marrow disorders will receive 1-5 blood units at home. Researchers will track how often transf…

This study looks at whether a new, detailed DNA test called ChromoSeq can work as well as current tests for people with myelodysplastic syndromes (MDS), a bone marrow disorder. About 60 adults with MDS will give samples, and doctors will compare the results and fill out surveys. …

This study looks at whether certain proteins in the blood (called cytokines) can help predict how well patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia will do on a milder type of chemotherapy (azacytidine). Researchers …

This study aims to find genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or tissue samples from up to 10,000 participants to understand how these changes cause cancer to progress. The goal…

This study follows people with inherited gene changes (especially in the DDX41 gene) that raise the risk of blood cancers like MDS and AML. Researchers will collect health information, blood, and other samples over 10 years to learn how these gene changes lead to cancer. Particip…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study collects blood, bone marrow, skin, saliva, and stool samples from 1,000 healthy adults aged 18 and older. The samples are used as a comparison to better understand myelodysplastic syndromes (MDS), a group of blood disorders that can lead to cancer. Participants do not …

This study tests whether measuring certain stem cells in people with myelodysplastic syndromes (MDS) can better predict disease relapse after a stem cell transplant. Researchers will use a special blood test to track these cells before and after transplant in 163 patients. The go…

This study collects blood, bone marrow, and tissue samples from up to 15,000 people with blood cancers or related disorders. The samples are stored and used for future research to better understand these diseases. Participants do not receive any treatment as part of this study. T…

This study gathers basic survival and complication information from 2000 people receiving stem cell transplants for blood cancers or immune diseases. The goal is to build a database for future research and to improve patient care. No new treatments are being tested; only standard…

This study looks at whether a new whole genome test called ChromoSeq can give doctors more detailed genetic information for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) than current tests. Researchers will compare ChromoSeq results to standard geneti…

This study collects blood, bone marrow, and other samples from people with non-cancerous blood diseases and their family members. Researchers will analyze DNA and other markers to find genetic causes and factors that affect disease severity and treatment response. The goal is to …

This study tests a telehealth program to help older adults (60+) with blood cancers like leukemia talk with their doctors about their care wishes. It aims to reduce anxiety and improve completion of advance directives. About 207 patients and their caregivers will participate remo…

This study aims to learn more about myelodysplastic syndromes (MDS) by following people with the condition and healthy volunteers over many years. Researchers will collect blood, bone marrow, and other samples to better understand how MDS progresses. No new treatments are tested;…

This study looks at how services from a non-profit cancer advocacy organization affect people with blood cancers like leukemia and lymphoma. Researchers will track 400 patients over time to see if the group's programs improve access to care, quality of life, and reduce financial …